Regentis Biomaterials has formalized a partnership with Humanitas Research Hospital in Milan, a leading orthopedic and sports medicine center, to support the commercial deployment of GelrinC across the European Union. This collaboration will leverage Humanitas’ high surgical volumes and translational research capabilities to strengthen surgeon engagement and expand Regentis’ clinical adoption infrastructure.

Professor Elizaveta Kon, Chief of the Translational Orthopedics Unit at Humanitas, brings extensive cartilage regeneration expertise and an H-index of 100 to the collaboration. She will spearhead the development of Regentis’ Centers of Excellence network and guide best practices for GelrinC use in clinical settings.

Regentis is establishing a network of European Centers of Excellence designed to train and support orthopedic surgeons in GelrinC implantation. These centers will provide professional guidance, knowledge sharing and serve as sites for the upcoming pivotal clinical trial, enhancing real-world experience and data collection.

GelrinC is a cell-free, off-the-shelf hydrogel implant with CE Mark approval for knee cartilage defects, offering a simple 10-minute procedure and sustained pain relief for over five years. With limited off-the-shelf alternatives available, GelrinC addresses a significant unmet need in cartilage repair and positions Regentis for European commercialization.